Javeed Froozan, MBA
Vice President, Business Development & Strategic Alliances, The Leukemia & Lymphoma Society
Javeed joined LLS in 2016 and leads the business, alliance, and portfolio management activities in support of the LLS Therapy Acceleration Program (TAP), Research programs, and other Mission focused initiatives. LLS TAP funding transactions include convertible note, equity, and research funding agreements with private and public companies, and research institutions developing novel products and services. Javeed has worked closely with LLS executives to generate clinical and economic value and manage risks for LLS, partners such as Forty Seven and X4 Pharmaceuticals, and other constituents by strengthening LLS agreements, corporate structure, process, and policies. Javeed’s corporate development experience spans over 25 years in early stage, growth, and large biopharmaceutical and health technology firms. This includes work to acquire over $150M worth of companies, products and technologies, enable two IPO’s in excess of $50M each, strategic sales and funding of projects worth millions of dollars, and to develop and launch new products. His experience also includes fostering investment and job creation with acquisitions of bio-manufacturing, R&D, and headquarters facilities using state and local economic development incentives. Prior to LLS, Javeed was at Emergent BioSolutions in its 10x revenue and market cap growth phase from 2003-2015 including leading the acquisition of Trubion Pharmaceuticals. He managed Emergent’s alliance with Pfizer to develop oncology and auto-immune therapeutic candidates, and to develop NuThraxTM, a novel, anthrax vaccine adjuvanted with CPG-7909. He worked with Baxter Healthcare on its cell therapy business focused on CD34+ cells to treat vascular ischemias. Additional work includes benchmarking technology transfer and venture creation, providing pro-bono guidance to entrepreneurs and scientists, and advising on economic planning for the Life Sciences industry Javeed obtained a B.S. in biology from The University of Michigan, Ann Arbor, and M.B.A. in economics and finance from The University of Michigan, Dearborn.